Company intelligence / Profile preview
STC Life
South Koreastcbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
STC Life claims to have developed the world's first pluripotent stem cell without side effects (STC-nEPS), holding over 58 associated patents, and focuses on therapies targeting aging, incurable diseases, and specific cancers. Collaborations include Fraunhofer Institute and preclinical studies in multiple indications, but no reported clinical trial data.
- Therapeutic areas
- Rare DiseasesGastroenterologyOtherOncologyNeurology
- Modalities
- Stem cell therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Fraunhofer Institute
Beyond the preview
Go deeper on STC Life.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STC Life.